Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Molecular-targeted therapy].

Tomohide Tamura1

  • 1Dept. of Internal Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC).

Future oncology (London, England)·2026
Same author

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Cancer science·2026
Same author

First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.

Advances in therapy·2023
Same author

First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.

Cancer medicine·2023
Same author

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Molecular-targeted therapy shows promise for lung cancer treatment. Epidermal growth factor receptor inhibitors are effective against cisplatin-resistant non-small cell lung cancer, warranting further clinical evaluation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer remains a leading cause of cancer-related mortality worldwide.
  • Molecular-targeted therapy offers a more precise approach to cancer treatment compared to traditional chemotherapy.
  • The development of targeted agents aims to inhibit specific molecular pathways driving tumor growth and progression.

Purpose of the Study:

  • To review the concept and current status of molecular-targeted therapy for lung cancer.
  • To highlight the progress of specific targeted agents, particularly epidermal growth factor receptor inhibitors.
  • To discuss the implications for future research and clinical application in lung cancer treatment.

Main Methods:

  • Literature review of preclinical and clinical studies on molecular-targeted therapy in lung cancer.

Related Experiment Videos

  • Analysis of data from phase II clinical trials of epidermal growth factor receptor inhibitors.
  • Synthesis of information on the mechanisms of action and clinical efficacy of targeted agents.

    • Main Results:

    • Molecular-targeted therapy represents a significant advancement in lung cancer treatment.
    • Epidermal growth factor receptor inhibitors demonstrate promising antitumor activity in phase II trials, especially in cisplatin-resistant non-small cell lung cancer.
    • These targeted agents offer a potential therapeutic option for patients with specific molecular alterations.

    Conclusions:

    • Molecular-targeted therapy, particularly with epidermal growth factor receptor inhibitors, holds significant potential for improving outcomes in non-small cell lung cancer.
    • Further rigorous clinical evaluation of these agents is crucial.
    • Enhanced collaboration between clinical oncologists and basic researchers is essential for optimizing the development and application of molecular-targeted therapies.